COVID-19 Acute Respiratory Distress Syndrome and Pulmonary Embolism: A Case Report of Nebulized Nitroglycerin and Systemic Thrombolysis For Right Ventricular Failure.
ARDS
COVID-19
nebulized nitroglycerin
pulmonary vasodilator therapy
right ventricular failure
thrombolysis
Journal
The Journal of emergency medicine
ISSN: 0736-4679
Titre abrégé: J Emerg Med
Pays: United States
ID NLM: 8412174
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
01
03
2021
revised:
19
05
2021
accepted:
03
07
2021
pubmed:
5
9
2021
medline:
31
12
2021
entrez:
4
9
2021
Statut:
ppublish
Résumé
Acute respiratory compromise caused by complications of COVID-19, such as acute respiratory distress syndrome (ARDS) or thromboembolic disease, is a complex syndrome with unique challenges in treatment. Management often requires time and intensive care through a multiprofessional, multispecialty approach. Initial management is particularly challenging within the limited-resource environment of the emergency department (ED). The emergency physician's toolbox of treatments with reasonably rapid onset remains limited to respiratory support, prone positioning, steroids, and anticoagulation. We present a case of a patient with COVID-19 complicated by ARDS and bilateral pulmonary emboli with severe right ventricular dysfunction and systemic hypotension treated with nebulized nitroglycerin and systemic thrombolytic therapy in the ED. Serial evaluation of right ventricular function using point of care ultrasound over the next 2 h showed improvement of function with both agents as well as improvement in the patient's respiratory rate and work of breathing. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: This case describes a novel use of a widely available medication for patients with COVID-19-induced right ventricular dysfunction. Nebulized nitroglycerin may be an option to improve right ventricular function when other inhaled pulmonary vasodilators are not available in the initial ED setting. © 2021 Elsevier Inc.
Sections du résumé
BACKGROUND
Acute respiratory compromise caused by complications of COVID-19, such as acute respiratory distress syndrome (ARDS) or thromboembolic disease, is a complex syndrome with unique challenges in treatment. Management often requires time and intensive care through a multiprofessional, multispecialty approach. Initial management is particularly challenging within the limited-resource environment of the emergency department (ED). The emergency physician's toolbox of treatments with reasonably rapid onset remains limited to respiratory support, prone positioning, steroids, and anticoagulation.
CASE REPORT
We present a case of a patient with COVID-19 complicated by ARDS and bilateral pulmonary emboli with severe right ventricular dysfunction and systemic hypotension treated with nebulized nitroglycerin and systemic thrombolytic therapy in the ED. Serial evaluation of right ventricular function using point of care ultrasound over the next 2 h showed improvement of function with both agents as well as improvement in the patient's respiratory rate and work of breathing. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: This case describes a novel use of a widely available medication for patients with COVID-19-induced right ventricular dysfunction. Nebulized nitroglycerin may be an option to improve right ventricular function when other inhaled pulmonary vasodilators are not available in the initial ED setting. © 2021 Elsevier Inc.
Identifiants
pubmed: 34479748
pii: S0736-4679(21)00552-7
doi: 10.1016/j.jemermed.2021.07.014
pmc: PMC8266546
pii:
doi:
Substances chimiques
Nitroglycerin
G59M7S0WS3
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e103-e107Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Acta Anaesthesiol Scand. 2021 May;65(5):629-632
pubmed: 33296498
J Thromb Thrombolysis. 2021 Apr;51(3):642-648
pubmed: 32809158
Chest. 1994 Sep;106(3):718-24
pubmed: 8082347
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Ann Card Anaesth. 2010 May-Aug;13(2):138-44
pubmed: 20442544
J Intensive Care Med. 2021 Mar;36(3):327-333
pubmed: 33234007
Am Heart J. 2017 Apr;186:100-110
pubmed: 28454823
Br J Haematol. 2020 Sep;190(5):e270-e274
pubmed: 32735730
J Pharmacol Exp Ther. 1997 Aug;282(2):985-94
pubmed: 9262367
J Intensive Care Med. 2021 Apr;36(4):500-508
pubmed: 33349095
J Intensive Care Med. 2015 May;30(4):209-16
pubmed: 24362445
ESC Heart Fail. 2021 Feb;8(1):714-718
pubmed: 33205620